文献速递肝病消化道肿瘤与早癌

化学诱导小鼠肝癌模型的突变图谱

Mutational landscape of a chemically-induced mouse model of liver cancer.
PubMed 文献 · J Hepatol · 2018-06-26

本研究对二乙基亚硝胺(DEN)诱导的小鼠肝细胞癌(HCC)肿瘤进行全外显子测序,并与未处理小鼠及人类HCC比较突变特征。DEN起始的肿瘤具有高且均匀的体细胞单核苷酸变异(SNV),可用六种已知COSMIC突变特征计算重建;每个肿瘤携带Hras第61密码子、Braf第584密码子或Egfr第254密码子的激活热点突变,21%的肿瘤发生Apc截短突变且均为癌。

要点

  • DEN诱导的小鼠肝癌肿瘤具有高且均匀的体细胞SNV负荷,插入缺失和拷贝数改变少。
  • 肿瘤外显子组的突变印记可用六种已知COSMIC突变特征计算重建。
  • 每个肿瘤均携带Hras第61密码子、Braf第584密码子或Egfr第254密码子的激活热点突变。

核心结论

  • 本研究详细描述了常用致癌物HCC小鼠模型中肿瘤的突变图谱,有助于未来利用该模型更好地理解人类疾病。

研究设计与样本

  • 对暴露于二乙基亚硝胺(DEN)的小鼠所产生的肝脏肿瘤进行全外显子测序,并比较DEN处理与未处理小鼠肝脏肿瘤及人类HCC的突变特征。

主要发现

  • DEN起始的肿瘤具有高且均匀的体细胞单核苷酸变异(SNV)数量,插入、缺失或拷贝数改变较少,与DEN已知的基因毒性作用一致。
  • 将肝细胞暴露于DEN后,在所得肿瘤外显子组中留下可重复的突变印记,可用六种已知COSMIC突变特征计算重建。
  • 肿瘤在许多癌基因和抑癌基因中携带高度多样性的低频非 synonymous 点突变,反映致癌物将SNV随机引入肝细胞基因组。
  • 鉴定出四个反复突变的基因,可能是该模型中HCC的致癌驱动基因。
  • 每个肿瘤均携带Hras第61密码子、Braf第584密码子或Egfr第254密码子的激活热点突变。

关键数值与推荐

  • 21%的肿瘤发生Apc截短突变,且均为癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Carcinogen-induced mouse models of liver cancer are used extensively to study the pathogenesis of the disease and are critical for validating candidate therapeutics. These models can recapitulate molecular and histological features of human disease. However, it is not known if the genomic alterations driving these mouse tumour genomes are comparable to those found in human tumours. Herein, we provide a detailed genomic characterisation of tumours from a commonly used mouse model of hepatocellular carcinoma (HCC). METHODS: We analysed whole exome sequences of liver tumours arising in mice exposed to diethylnitrosamine (DEN). Mutational signatures were compared between liver tumours from DEN-treated and untreated mice, and human HCCs. RESULTS: DEN-initiated tumours had a high, uniform number of somatic single nucleotide variants (SNVs), with few insertions, deletions or copy number alterations, consistent with the known genotoxic action of DEN. Exposure of hepatocytes to DEN left a reproducible mutational imprint in resulting tumour exomes which we could computationally reconstruct using six known COSMIC mutational signatures. The tumours carried a high diversity of low-incidence, non-synonymous point mutations in many oncogenes and tumour suppressors, reflecting the stochastic introduction of SNVs into the hepatocyte genome by the carcinogen. We identified four recurrently mutated genes that were putative oncogenic drivers of HCC in this model. Every neoplasm carried activating hotspot mutations either in codon 61 of Hras, in codon 584 of Braf or in codon 254 of Egfr. Truncating mutations of Apc occurred in 21% of neoplasms, which were exclusively carcinomas supporting a role for deregulation of Wnt/β-catenin signalling in cancer progression. CONCLUSIONS: Our study provides detailed insight into the mutational landscape of tumours arising in a commonly used carcinogen model of HCC, facilitating the future use of this model to better understand the human disease. LAY SUMMARY: Mouse models are widely used to study the biology of cancer and to test potential therapies. Herein, we have described the mutational landscape of tumours arising in a carcinogen-induced mouse model of liver cancer. Since cancer is a disease caused by genomic alterations, information about the patterns and types of mutations in the tumours in this mouse model should facilitate its use to study human liver cancer.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Connor F, Rayner TF, Aitken SJ, et al. Mutational landscape of a chemically-induced mouse model of liver cancer. J Hepatol. 2018. PMID: 29958939. doi:10.1016/j.jhep.2018.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。